A worldwide standard guideline for treating HF is to inhibit the chronically activated sympathetic nervous system in HF patients, and renin-angiotensin system inhibitors and β-adrenoceptor antagonists (β-blockers) are the main therapies used for this purpose [4]. This evidence concerns the gene REN and hydrops fetalis.